Results 211 to 220 of about 7,128 (244)

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

Pediatric Dermatology, EarlyView.
ABSTRACT Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children.
Alexa Moschella, Celina DeBiasio, Carmen Liy‐Wong   +2 more
wiley   +1 more source

Generative Artificial Intelligence Tools: Evaluating Ways to Automate Your SALT (GATEWAYS) Scoring of Alopecia Areata

Pediatric Dermatology, EarlyView.
ABSTRACT Background Alopecia areata (AA) is an autoimmune disease affecting hair follicles that results in nonscarring hair loss. AA impacts 0.1%–0.2% of the United States population, with pediatric patients accounting for 16.0%–27.7% of all cases.
Radhika Gupta, Hojjat Salmasian, Michelle Oboite, Sarah Mehlmann, Griffin Stockton Hogrogian, Leslie Ann Castelo‐Soccio, George Cotsarelis, Albert C. Yan   +7 more
wiley   +1 more source

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E. Myers, Pinaki Biswas, Irene Hernández‐Martín, Erman Güler, Marina Mikheil, Raj Chovatiya   +10 more
wiley   +1 more source

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris   +10 more
wiley   +1 more source

Janus kinases and Src family kinases in the regulation of EGF induced vimentin expression in MDA-MB-468 breast cancer cells

, 2016
Teneale A. Stewart, Iman Azimi, Andrew J. Brooks, Erik W. Thompson, Sarah J. Roberts‐Thomson, Gregory R. Monteith   +5 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Janus-Kinase-Hemmer

Zeitschrift für Rheumatologie, 2012
Die Janus-Kinase-Inhibitoren stellen einen neuen therapeutischen Ansatz in der Behandlung der rheumatoiden Arthritis dar. In Phase-II- und -III-Studien zu Tofacitinib zeigte sich eine gute klinische Wirksamkeit mit einem ACR (American College of Rheumatology)-20-Ansprechen von > 50% sowohl fur die Mono- als auch die Kombinationstherapie mit Methotrexat.
E. Ostermeier, P. Roll, H.-P. Tony
openaire   +1 more source

Janus Kinase Mutations

Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire   +2 more sources

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources

Malignancy and Janus Kinase Inhibition

Rheumatic Disease Clinics of North America, 2017
The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population.
Padmapriya, Sivaraman, Stanley B, Cohen
openaire   +2 more sources